CDK4/6 inhibitor for small cell lung cancer is launched in the U.S., Simcere has development rights in Greater China
Author: HE Sheng Recently the CDK4/6 inhibitor Cosela (trilaciclib), developed by G1Therapeutics, was launched...
Other projects
2020 Top Ten Chinese Biomedicine Licensing-in Agreements
Author: HE Sheng In China, licensing in has become a key link in the new drug research and development industry...
In Hurun’s 2020 Top 500 Chinese Private Enterprises, Hengrui and Mindray Lead the Healthcare Category
Author: HE Sheng Recently, the Hurun Research Institute released their list of "Hurun’s 2020 Top Chinese 500...
AIDS Day Feature | China has Four Domestically Developed New Drugs
Author: MyBioGate December 1, 2020 is the 33rd "World AIDS Day" with the theme: "Ending the HIV/AIDS Epidemic:...
0 Comments